ArticlePloS one2019
Lysozyme as the anti-proliferative agent to block the interaction between S100A6 and the RAGE V domain.
Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 33 citations in OpenAlex.
- Exploring tear biomarkers with shotgun proteomics for retinoblastoma diagnosis: a pilot study.The journal of liquid biopsy · 2026Article
- Interaction of Lysozyme with Sulfated β-Cyclodextrin: Dissecting Salt and Hydration Contributions.Molecules (Basel, Switzerland) · 2026Article
- Lysozyme Functionalized Alginate-Chitosan Beads and Films for Different Release Applications.Gels (Basel, Switzerland) · 2026Article
- Multifaceted roles of S100A6 in neurological disorders: expression, interaction networks, and clinical implications.Frontiers in pharmacology · 2026Review
- Is there sufficient evidence to support the health benefits of including donkey milk in the diet?Frontiers in nutrition · 2024Review
- Digital spatial profiling identifies molecular changes involved in development of colitis-associated colorectal cancer.Frontiers in oncology · 2024Article
- S100A6: molecular function and biomarker role.Biomarker research · 2023Review
- Independent antioxidant and anticancer properties of a novel thermostable lysozyme isolated from3 Biotech · 2023Article
- Identification of Protein Quality Markers in Toad Venom fromMolecules (Basel, Switzerland) · 2023Article
- S100A6 Protein-Expression and Function in Norm and Pathology.International journal of molecular sciences · 2023Review
- High-accuracy prediction of colorectal cancer chemotherapy efficacy using machine learning applied to gene expression data.Frontiers in physiology · 2023Article
- Lysozyme and Its Application as Antibacterial Agent in Food Industry.Molecules (Basel, Switzerland) · 2022Review
- Recombinant expression of hen egg white lysozyme with the assistance of xylanase fusion partner inBioengineered · 2022Article
- Advancements in Biodegradable Active Films for Food Packaging: Effects of Nano/Microcapsule Incorporation.Foods (Basel, Switzerland) · 2022Review
- Synthesis of Novel Suramin Analogs With Anti-Proliferative ActivityFrontiers in chemistry · 2021Article
- Recent Insights Into the Prognostic and Therapeutic Applications of Lysozymes.Frontiers in pharmacology · 2021Review
- The interactions of the ruthenium(II)-cymene complexes with lysozyme and cytochrome c.Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry · 2020Article
- FRET-Based Aptasensor for the Selective and Sensitive Detection of Lysozyme.Sensors (Basel, Switzerland) · 2020Article
- Biophysical Insight into the Interaction of Human Lysozyme with Anticancer Drug Anastrozole: A Multitechnique Approach.TheScientificWorldJournal · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this report, using NMR and molecular modeling, we have studied the structure of lysozyme-S100A6 complex and the influence of tranilast [N-(3, 4-dimethoxycinnamoyl) anthranilic acid], an antiallergic drug which binds to lysozyme, on lysozyme-S100A6 and S100A6-RAGE complex formation and, finally, on cell proliferation. We have found that tranilast may block the S100A6-lysozyme interaction and enhance binding of S100A6 to RAGE. Using WST1 assay, we have found that lysozyme, most probably by blocking the interaction between S100A6 and RAGE, inhibits cell proliferation while tranilast may reverse this effect by binding to lysozyme. In conclusion, studies presented in this work, describing the protein-protein/-drug interactions, are of great importance for designing new therapies to treat diseases associated with cell proliferation such as cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.